Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

The researchers first tested their hypothesis by delivering ODN directly to the hindbrain of rats. Once treated, the rats ...

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Donald Trump issues new warning to Iran, threatens to attack again Popular pharmacy chain files Chapter 11 bankruptcy facing ...